Breakthrough Presbyopia Treatment LNZ100 Gains Global Momentum After US Launch

A new treatment for presbyopia, a common age-related vision condition, has made significant progress in global markets. LNZ100, a once-daily prescription eye drop, received US approval in July 2025 and launched commercially three months later. The drug has also entered regulatory review in China, where presbyopia affects nearly everyone by the age of 52. LNZ100 demonstrated strong results in clinical trials. It met its primary goal and key secondary targets in a Phase 3 study, showing clear improvements in near vision while maintaining a well-tolerated safety profile. The active ingredient, aceclidine, works by contracting the pupil, creating a pinhole effect that sharpens close-up sight without harming distance vision.

Everest Medicines has secured the rights to develop, manufacture, and sell LNZ100 across Greater China. The company submitted a New Drug Application (NDA) to Chinese regulators in September 2025, with approval anticipated by early 2027. Under the agreement, Everest will pay an upfront fee and additional milestone payments to Corxel Pharmaceuticals Limited, the drug’s original developer. Following the deal, Corxel will shift its focus entirely to cardiometabolic therapies. Everest’s Chairman, Yifang Wu, described LNZ100 as a standout product with strong commercial potential in addressing presbyopia, a condition that impacts nearly 100% of China’s population over 52.

LNZ100 is now available in the US after its October 2025 launch. In China, the drug awaits regulatory approval, with a decision expected in early 2027. The treatment’s success in trials and its unique mechanism position it as a promising option for millions affected by presbyopia.